Company Encyclopedia
View More
name
CHINA REFORM HEALTH
000503.SZ
China Reform Health Management and Services Group Co., Ltd. offers medical insurance management services in China. It provides services of medical insurance funds, medical quality and safety, drug and device supervision, and internet health protection. It is also involved in the pharmaceutical and medical business.
402.16 B
000503.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Health Care DistributorsIndustry
Industry Ranking23/25
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-8.87%D
    • Profit Margin-36.03%E
    • Gross Margin1.31%E
  • Growth ScoreD
    • Revenue YoY-11.44%E
    • Net Profit YoY-5273.56%E
    • Total Assets YoY8.62%B
    • Net Assets YoY-8.82%D
  • Cash ScoreD
    • Cash Flow Margin-277.56%D
    • OCF YoY-11.44%E
  • Operating ScoreD
    • Turnover0.17D
  • Debt ScoreB
    • Gearing Ratio37.02%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Zhitong A-share lock-up release overview | October 9

    On October 9th, a total of 11 listed companies had their restricted shares unlocked, with a total market value of approximately 24.303 billion yuan. The specific situation of the restricted share unlocks today is as follows: | Stock Abbreviation | Stock Code | Restricted Share Type | Number of Unlocks | | -------------------- | ------------ | ----------------------- | -------------------- | | CHINA REFORM HEALTH | 000503 | Equity Incentive Restricted Circulation | 1.6798 million | | Kangyuan Pharmaceutical | 600557 | Equity Incentive Restricted Circulation | 315,500 | | Sentech Co., Ltd. | 603098 | Equity Incentive Restricted Circulation | 270,000 | | SRX | 605168 | Equity Incentive Restricted Circulation | 165,300 | | VASTDATA | 603138 | Equity Incentive Restricted Circulation | 5.6629 million | | Tianyi Medical | 301097 | Extended Restricted Lock-up Period Circulation | 40.6 million | | Minglida | 301268 | Extended Restricted Lock-up Period Circulation | 190 million | | HENGYU DATACOM | 300965 | Extended Restricted Lock-up Period Circulation | 35.1045 million | | RIGOL | 688337 | 1.18 billion | | Zhongfu Shenying | 688295 | 2.98 billion | | Changguang Huaxin | 688048 | 700 million |

    Zhitong·
    SZ
    000503
    +0.62%
    SH
    688337
    +1.52%
    SZ
    300965
    +1.82%
    Zhitong·
    SZ
    000503
    +0.62%
    SH
    688337
    +1.52%
    SZ
    300965
    +1.82%

    CHINA REFORM HEALTH: The controlling shareholder and its concerted parties have completed the billion-yuan increase plan

    CHINA REFORM HEALTH announced that its controlling shareholder China Oceanwide Holdings and its concerted party China Reform Development completed their shareholding increase plan on September 26, 2025, with an increase amount of approximately 100 million yuan, raising their shareholding ratio from 26.48% to 27.44%. The purpose of the increase is based on confidence in the company's development and to stabilize the stock price. The increase is compliant and has not affected the listing conditions and actual control rights, with a commitment not to reduce holdings within the statutory period

    Zhitong·
    SZ
    000503
    +0.62%
    Zhitong·
    SZ
    000503
    +0.62%

    CHINA REFORM HEALTH: Unanimous shareholders increased their holdings by 7.6813 million shares

    CHINA REFORM HEALTH announced that CHINA REFORM DEVELOPMENT increased its holdings by a total of 7.6813 million shares through centralized bidding from September 17, 2025, to September 19, 2025, accounting for 0.78% of the company's total share capital, with a transaction amount of 81.1461 million yuan; after the increase, its holdings reached 31.8053 million shares, accounting for 3.24%. China Oceanwide and its concerted parties collectively hold 268 million shares, accounting for 27.26%. This equity change touches on an integer multiple of 1%, and the increase plan is still being implemented

    Zhitong·
    SZ
    000503
    +0.62%
    Zhitong·
    SZ
    000503
    +0.62%

    CHINA REFORM HEALTH: The company's independent director Bai Yan has passed away due to illness

    On the evening of September 4th, CHINA REFORM HEALTH announced that the company's board of directors recently learned that independent director Bai Yan unfortunately passed away due to illness on August 31, 2025. The company and its board of directors express their deep condolences for Bai Yan's passing and extend heartfelt sympathies to his family

    Zhitong·
    SZ
    000503
    +0.62%
    Zhitong·
    SZ
    000503
    +0.62%

    CHINA REFORM HEALTH released its performance for the first half of the year, with a net loss attributable to the parent company of 99.0907 million yuan

    According to the Zhitong Finance APP, CHINA REFORM HEALTH released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 95.5301 million yuan, a year-on-year decrease of 30.47%. The net loss attributable to shareholders of the listed company was 99.0907 million yuan, and the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 98.8113 million yuan, with a basic loss per share of 0.1012 yuan

    Zhitong·
    SZ
    000503
    +0.62%
    Zhitong·
    SZ
    000503
    +0.62%
    © 2025 Longbridge｜Disclaimer